AlphaCentric Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

AlphaCentric Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-20,000	Closed	-$1.46M	–	291
2024 Q3	$1.46M	Hold	20,000	–	–	1.09%	28
2024 Q2	$1.37M	Hold	20,000	–	–	1.01%	30
2024 Q1	$1.38M	Hold	20,000	–	–	0.83%	46
2023 Q4	$1.43M	Sell	20,000 -5,500	-22%	-$316K	0.96%	36
2023 Q3	$1.33M	Hold	25,500	–	–	0.75%	42
2023 Q2	$1.61M	Hold	25,500	–	–	0.9%	41
2023 Q1	$1.38M	Buy	25,500 +18,000	+240%	+$870K	0.95%	29
2022 Q4	$397K	Buy	+7,500	New	+$376K	0.39%	83
2021 Q4	–	Sell	-4,000	Closed	-$149K	–	280
2021 Q3	$149K	Sell	4,000 -1,000	-20%	-$34.8K	0.04%	137
2021 Q2	$204K	Sell	5,000 -2,000	-29%	-$73.9K	0.06%	106
2021 Q1	$238K	Sell	7,000 -1,000	-13%	-$34.7K	0.08%	84
2020 Q4	$254K	Buy	8,000 +7,450	+1,355%	+$196K	0.11%	53
2020 Q3	$14K	Buy	+550	New	+$12.5K	0.01%	151

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

AlphaCentric Advisors's ITCI Position: Q4 2024 in Review

AlphaCentric Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2024, closing a stake of 20,000 shares — an estimated $1.46M sold.

AlphaCentric Advisors first reported a position in ITCI in Q3 2020 and held it in 13 quarters. The position peaked at $1.61M in Q2 2023. 387 funds tracked by Wall St. Rank hold ITCI as of Q4 2024.

AlphaCentric Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2024 after selling out during the quarter.
AlphaCentric Advisors sold 20,000 Intra-Cellular Therapies Inc. shares in Q4 2024, an estimated $1.46M.
AlphaCentric Advisors first reported a position in Intra-Cellular Therapies Inc. in Q3 2020 and held it in 13 quarters.
AlphaCentric Advisors's Intra-Cellular Therapies Inc. position peaked at $1.61M in Q2 2023.
387 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.